Table 4– Characteristics of patients with pulmonary hypertension associated with chronic obstructive pulmonary disease (COPD) and mean pulmonary artery pressure (PAP) ≥40 mmHg by treatment group
Receiving compassionate vasodilator therapyStandard managementp-value
Subjects n4316
Age years70±1070±60.826
Female %30310.940
Exercise limitation
 WHO-FC III/IV %60/4073/270.341
 ISWD m40 (15–120)55 (33–100)0.616#
Right heart catheter
 Entrained O2 L·min−13.0 (0–5.5)2.0 (0–5.3)0.439#
 Resting SpO2 %95±493±30.126
 Mean RAP mmHg12±513±70.573
 Mean PAP mmHg51±745±80.015
 CI L·min·m−22.3±0.72.9±0.80.016
 PCWP mmHg11±315±60.016
 PVR dyn·s·cm−5839±350508±3530.004
SvO2 %62±867±100.052
Pulmonary function tests
 FEV1 % pred71±2350±180.003
 FVC % pred95±2376±240.010
DLCO % pred26±1329±120.532
CT scan
 Total emphysema score9 (2–18.3)10.5 (1.9–15.7)0.876#
 Total fibrosis score0.5 (0–3.3)0 (0–1.5)0.199#
  • Data are presented as mean±sd or median (interquartile range), unless otherwise stated. Total emphysema score represents the sum total of emphysema scores for all six lung zones; total fibrosis score represents sum total of fibrosis scores for all six lung zones. WHO-FC: World Health Organization functional class; ISWD: incremental shuttle walking distance; SpO2: arterial oxygen saturation measured by pulse oximetry; RAP: right atrial pressure; CI: cardiac index measured by thermodilution method; PCWP: pulmonary capillary wedge pressure; PVR: pulmonary vascular resistance; SvO2: mixed venous oxygen saturation; FEV1: forced expiratory volume in 1 s; % pred: % predicted; FVC: forced vital capacity; DLCO: diffusing capacity of the lung for carbon monoxide; CT: computed tomography. #: Mann–Whitney U-test used for nonparametric data.